Company news
Royalty Pharma Plc (NASDAQ:RPRX) news
Royalty Pharma Plc news releases on 6ix. Latest, Oct 11, 2023: Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
Press releases — page 3
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 10, 2023
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 20, 2023
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
August 23, 2023
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 23, 2023
Royalty Pharma Reports Second Quarter 2023 Results
August 7, 2023
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 17, 2023
Royalty Pharma Declares Third Quarter 2023 Dividend
July 16, 2023
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 6, 2023
Royalty Pharma Reports First Quarter 2023 Results
May 8, 2023
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 2, 2023
Royalty Pharma Declares Second Quarter 2023 Dividend
April 16, 2023
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 12, 2023
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 26, 2023
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 22, 2023
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
March 22, 2023
Royalty Pharma Raises Full Year 2023 Guidance
March 14, 2023
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
February 28, 2023
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 14, 2023
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 17, 2023
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 8, 2023
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 8, 2023
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
January 8, 2023
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
January 3, 2023
Royalty Pharma Announces Expansion of Senior Leadership Team
December 14, 2022
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 27, 2022
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 8, 2022
Royalty Pharma Reports Third Quarter 2022 Results
November 7, 2022
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
October 17, 2022
Royalty Pharma Declares Fourth Quarter 2022 Dividend
October 16, 2022
Royalty Pharma Announces R&D Funding Collaboration With Merck
October 11, 2022
Royalty Pharma Announces Expansion of Leadership Team
October 11, 2022
Royalty Pharma Reports Second Quarter 2022 Results
August 3, 2022
Royalty Pharma Declares Third Quarter 2022 Dividend
July 14, 2022
Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 13, 2022
Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million
July 12, 2022
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
June 29, 2022
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
May 22, 2022
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
May 16, 2022
Royalty Pharma Reports First Quarter 2022 Results
May 4, 2022
Royalty Pharma Declares Second Quarter 2022 Dividend
April 17, 2022
Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022
April 12, 2022
Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment
March 28, 2022
Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference
March 2, 2022
Royalty Pharma Announces Inaugural Investor Day
February 15, 2022
Royalty Pharma Reports Q4 and Full Year 2021 Results
February 14, 2022
Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022
January 19, 2022
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference
January 9, 2022
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
January 6, 2022
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
January 6, 2022